Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Dec 1;88(4):340–347. doi: 10.1097/QAI.0000000000002781

Table 1.

Key Model Parameters and Description of the Model Scenarios

Key Model Parameters (Full methodological details are provided in Supplemental Technical Appendix)
Weekly Screening Rates – Undiagnosed (All Races) 1.28%
Weekly Probability of Initiating ART - Diagnosed
 Black 12.5%
 Hispanic 15.8%
 White 16.4%
Weekly Probability of Stopping ART – Treated by ART
 Black 0.09%
 Hispanic 0.09%
 White 0.084%
Probability of Starting PrEP After a Negative HIV Test (All Races) 68.5%
Weekly Probability of Stopping PrEP While Eligible (All Races) 2.6%
Primary Scenarios (Increasing PrEP Coverage at Empirical ART Coverage)
ART Coverage1 (Proportion of Virally Suppressed2) 88.2% (65.0%)
PrEP Coverage3
 Reference 25%
 Experimental 37.5% to 75% (4 levels)
Total: 5 scenarios (5 levels of PrEP over 1 level of ART)
Secondary Scenarios (Increasing PrEP Coverage at Counterfactual ART Coverage)
ART Coverage1 (Proportion of Virally Suppressed2)
 Low ART 75.1% (51.2%)
 Empirical ART 88.2% (65.0%)
 High ART 99.5% (72.9%)
PrEP Coverage3
 Reference 0% *
 Experimental 12.5% to 75% (6 levels)
Total: 21 scenarios (7 levels of PrEP over 3 levels of ART Coverage)

San Francisco calibrated values

*

Changes in PrEP coverage at a given ART Coverage is compared to 0% PrEP at the same ART Coverage

1

Proportion of ART users among individuals with diagnosed HIV infection

2

Proportion of HIV-infected MSM who are virally suppressed

3

Proportion of PrEP users among PrEP eligible at any time point